Psychiatry · Antipsychotic
The FDA's approval of Alembic's generic Haloperidol introduces significant competition in the psychiatry market, which could pressure pricing and market share for existing branded products. Portfolio teams must evaluate the implications of this increased competition on their strategies and pricing models.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/30/2026, 12:32:40 AM
Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Alembic's generic Haloperidol introduces significant competition in the psychiatry market, which could pressure pricing and market share for existing branded products. Portfolio teams must evaluate the implications of this increased competition on their strategies and pricing models. Regulatory context from FDA (FDA AP — HALOPERIDOL (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (7 high-relevance).
Strategic implications for portfolio teams include assessing the impact of increased competition on pricing and market share for Haloperidol. The strongest clinical anchor is Pediatric Long-Term Follow-up and Rollover Study (ClinicalTrials.gov), sponsor/company relevance (novartis). In Psychiatry · Antipsychotic, 4 regulatory and 4 competitive items passed relevance filtering for Alembic Pharmaceuticals.
The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This approval allows Alembic to enter the market with a generic version of Haloperidol, potentially increasing competition against existing branded products.
Regulatory risk is concentrated around FDA AP — HALOPERIDOL (ORIG) (FDA). Entity match (haloperidol); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.
FDA AP — HALOPERIDOL (ORIG)
FDAhigh relevance
Entity match (haloperidol); Regulatory pathway relevance (nda)
FDA document
View sourceFDA TA — ANDA220639
FDAhigh relevance
Entity match (alembic pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View sourceClinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceNotice: Register of authorised online sellers of medicines in Northern Ireland
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourcePediatric Long-Term Follow-up and Rollover Study
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceStudy to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourcectHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceEvaluation of Adverse Effects Related to Prescribed Medications in Periodontology Clinic
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceSPI-1005 in Adults Receiving Cochlear Implant
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceIGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceU.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceFDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Orders Azurity Pharmaceuticals to Halt Distribution of Unapproved Compounding Kits
Humanexa Signalsmedium relevance
Moderate corpus alignment
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceGut Proteobacteria glycine metabolism regulates neuroplasticity, motivation, and reinstatement of cocaine self-administration in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceTwo-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Alembic's generic Haloperidol introduces significant competition in the psychiatry market, which could pressure pricing and market share for existing branded products. Portfolio teams must evaluate the implications of this increased competition on their strategies and pricing models.
The entry of a generic competitor may lead to reduced prices and market share for existing branded Haloperidol products, impacting revenue streams.
The approval indicates compliance with FDA standards, but does not suggest immediate regulatory challenges for existing products.
Monitor market entry timelines and pricing strategies from Alembic and competitors.
Track for follow-up milestones; no immediate action required.